Abbott Faces Lawsuit Over Faulty Glucose Sensor
A plaintiff claims a defective FreeStyle Libre 3 Plus sensor led to an unnecessary emergency room visit.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Should medical device companies be held strictly liable for inaccurate data causing patient emergency room visits?
Andrew Vincent has filed a product liability lawsuit against Abbott Laboratories, alleging a defective FreeStyle Libre 3 Plus sensor reported dangerously low blood sugar levels. The plaintiff contends these inaccurate readings forced an emergency medical visit that hospital testing later failed to confirm.
Why it matters
This litigation highlights ongoing concerns regarding the reliability of continuous glucose monitoring technology. It follows a series of high-profile recalls involving millions of sensors that the FDA previously classified as Class I, the agency's most serious designation.
Abbott previously recalled more than 3 million FreeStyle Libre 3 and Libre 3 Plus sensors in November 2025, which the FDA classified as a Class I event in January 2026. This follows a separate July 2024 recall for false readings that also reached Class I status.
The players
Andrew Vincent
He is the plaintiff who filed a product liability lawsuit against Abbott after an emergency room visit prompted by inaccurate sensor readings.
Abbott Laboratories
It is a global healthcare company that manufactures medical devices, including continuous glucose monitoring systems for diabetes management.
Abbott Diabetes Care Inc.
This subsidiary specializes in developing technology for patients with diabetes and is a named defendant in the current litigation.
The details
The lawsuit, filed in New York Supreme Court, claims Abbott failed to provide adequate warning about the risks associated with the sensor technology. Vincent seeks damages after relying on device data that triggered an emergency response unsupported by hospital blood sugar tests.
Timeline
July 2024: Abbott initiated a recall for FreeStyle Libre 3 sensors due to falsely elevated readings.
September 2024: The FDA formally classified the July 2024 recall as Class I.
November 2025: Abbott initiated a recall for more than 3 million Libre 3 and 3 Plus sensors.
January 2026: The FDA classified the November 2025 recall as Class I.
October 20, 2026: Andrew Vincent filed the product liability lawsuit in New York Supreme Court.
The Big Picture
The current litigation follows a pattern of heightened regulatory and legal scrutiny established by the FDA Class I recall classification system. This classification is reserved for situations where there is a reasonable probability that the use of a product will cause serious adverse health consequences or death.
Users of continuous glucose monitoring systems should remain vigilant for symptoms that do not align with device readings and perform confirmatory tests when necessary. Patients concerned about the safety of their devices can consult with their healthcare provider to review recent FDA safety advisories.
The takeaway
Patients using automated medical devices should always treat sensor data as a secondary tool rather than the sole source of truth for urgent medical decisions. Cross-referencing device alerts with clinical symptoms remains a critical safety step for those managing chronic conditions.
Further reading
For more information on the evolving landscape of glucose management, visit the United States Diabetes section.
Source note: This article includes information reported by AboutLawsuits.
Live Poll
Should medical device companies be held strictly liable for inaccurate data causing patient emergency room visits?
